
    
      A Non-Interventional Study on the Tolerability and Efficacy of Octagam 5% or 10% or panzyga.
      Patients with any indication (replacement and immonomodulation) as prescribed by the treating
      physician. Marketed Octagam 5% or 10% or panzyga will be used according to the investigator
      prescription; intravenous (iv) administration.The primary objective is to detect and evaluate
      adverse drug reactions (ADRs) occurring during or after the administration of Octagam or
      panzyga in any indication, age group or treatment regimen, where a causal relationship to the
      administration of Octagam or panzyga is suspected.
    
  